Central Government New Programme To Promote Research In Pharma Centeral Government

New Delhi: Finance Minister Nirmala Sitharaman announced launch of a new programme to promote research in pharmaceuticals with a view to promoting growth of the sector. She also said facilities in select ICMR (Indian Council of Medical Research) labs will be made available for research by public and private medical faculties.

The domestic pharma industry had demanded that Budget 2023-24 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry. The Organization of Pharmaceutical Producers of India had demanded that the government encourage the transition to a discovery-oriented and science-driven approach by offering fiscal incentives and supportive policies in order for the life sciences sector to truly contribute to the vision of Aatmanirbhar Bharat.

Charu Sehgal, Partner, Deloitte India said,” The announcement of providing investment and setting up centres of excellence to promote research and development in pharma is much needed and will help India move up the value chain in the life sciences sector.   The focus on providing skilled manpower availability for high-end research and manufacturing in the medical technology sector will help India become more self reliant and reduce the current high dependence on imports, Sehgal added.

  • Related Posts

    • Pharma
    • April 26, 2025
    • 126 views
    Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

    Mumbai:  Suven Pharmaceuticals Limited, a contract development and manufacturing organization (CDMO), has announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers,…

    • Pharma
    • April 26, 2025
    • 105 views
    Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

    India’s largest diagnostics service provider, Dr Lal PathLabs (DLPL), on Friday reported an 81.4 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the March quarter of financial year…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

    Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

    Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

    Dr Lal PathLabs Q4 profit rises 81% on volume growth, geographic expansion

    Lupin-led price cut slashes cost of key TB drug pretomanid by 25%

    Lupin-led price cut slashes cost of key TB drug pretomanid by 25%

    250% rally in one year! Multibagger pharma stock jumps despite stock market crash

    250% rally in one year! Multibagger pharma stock jumps despite stock market crash